Piramal Enterprises hits over 2-year high after strong performance in Q1
In Q1FY22, pharma segment delivered robust revenue growth of 31 per cent YoY, led by the Complex Hospital Generics (CHG) and India Consumer Products (ICP) businesses.
Piramal Enterprises Ltd - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Piramal Enterprises Q1 profit up 8% to Rs 534 crore
Consolidated revenue from operations of the company stood at Rs 2,908.68 crore for the quarter under consideration against Rs 2,937.34 crore for the same period a year ago, it added. PIRAMAL ENTERPRISES LTD. - 500302 - Auditor'S Report On The Financial Results For The Quarter Ended 30Th June, 2021
Dear Sir / Madam, In continuation to our financial results for the quarter ended 30th June, 2021 filed with the stock exchanges after the Board Meeting held today, please find attached independent auditor's reports on these financial results with Unique Document Identification Number. This is also available on the Company''s website at www.piramal.com Thanking you, Q1FY22 Result Announced for Piramal Enterprises Ltd.
Consolidated Financial Highlights P&L; Performance: - Q1 FY22 revenues of INR 2,909 Cr, broadly stable year over year Q1 FY22 Net Profit at INR 534 Cr, increased 8% year over year Balance Sheet: - Equity increased by 29% to INR 34,996 Cr. since March 2019 50% reduction in Net Debt by INR 27,677 Cr. since March 2019 PEL Net Debt-to-Equity at 0.8x DHFL Acquisition – Significant progress made in Q1 FY22: - Resolution Plan received approval from NCLT and Monitoring Committee appointed in June 2021 Implementation of the Resolution Plan is in progress - To be completed within 90 days of NCLT approval, as per regulatory requirement. Ajay Piramal, Chairman, Piramal Enterprises Ltd. said, “Despite the impact of the second wave of Covid-19, we have delivered a resilient performance during the quarter with Revenues at INR 2,909 Crores, Net Profit YoY growth by 8% to INR 534 Crores. We continue to maintain a strong balance sheet, with the net debt-to-equity ratio at 0.8x. In Financial Services, our resolution plan for DHFL’s acquisition received NCLT-approval in June-2021. We are on track with the Monitoring Committee mandate for the completion of this transaction within 90 days from NCLT approval. After successfully going through the recent consolidation phase, we are now transitioning from a wholesale-led to a well-diversified Financial Services business. The transition augmented by the DHFL acquisition will not only bring quantum growth in our loan book but also create a large India-wide platform that will enable us to deliver sustained growth and profitability in the years to come. Our Pharma business continues to deliver robust performance during the quarter, with 31% YoY revenue growth, indicating the strength of our business model. In addition, post the capital raise from the Carlyle Group, we have accelerated on our two-pronged strategic growth trajectory though investments in both organic and inorganic initiatives. While we remain cautiously optimistic for FY22, we see a strong runway for growth across both our businesses. Our immediate focus will be to effectively integrate DHFL with our Financial Services organization. Pursuant to which, we will be better positioned to announce our plan to create two separate listed entities in Financial Services and Pharma.” Result PDF Piramal Enterprises Ltd - 500302 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Statement of deviation(s) or variation(s) for the quarter ended 30th June, 2021 Piramal Enterprises Ltd - 500302 - Unaudited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June, 2021
Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2021 Piramal Enterprises Ltd - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Conference Call with Investors/ Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015